Scholars@Duke

Government Funding for the Development of Enzalutamide.

Publication ,  Journal Article
Gyawali, B; Jung, EH; Mooney, H; Avorn, J; Kesselheim, AS
Published in: JAMA oncology
February 2025
Published version (DOI)

Duke Scholars

Emily Jung
Author Emily Jung  

Published In

JAMA oncology

DOI

10.1001/jamaoncol.2024.5661

EISSN

2374-2445

ISSN

2374-2437

Publication Date

February 2025

Volume

11

Issue

2

Start / End Page

182 / 183

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 1117 Public Health and Health Services
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gyawali, B., Jung, E. H., Mooney, H., Avorn, J., & Kesselheim, A. S. (2025). Government Funding for the Development of Enzalutamide. JAMA Oncology, 11(2), 182–183. https://doi.org/10.1001/jamaoncol.2024.5661
Gyawali, Bishal, Emily H. Jung, Helen Mooney, Jerry Avorn, and Aaron S. Kesselheim. “Government Funding for the Development of Enzalutamide.” JAMA Oncology 11, no. 2 (February 2025): 182–83. https://doi.org/10.1001/jamaoncol.2024.5661.
Gyawali B, Jung EH, Mooney H, Avorn J, Kesselheim AS. Government Funding for the Development of Enzalutamide. JAMA oncology. 2025 Feb;11(2):182–3.
Gyawali, Bishal, et al. “Government Funding for the Development of Enzalutamide.” JAMA Oncology, vol. 11, no. 2, Feb. 2025, pp. 182–83. Epmc, doi:10.1001/jamaoncol.2024.5661.
Gyawali B, Jung EH, Mooney H, Avorn J, Kesselheim AS. Government Funding for the Development of Enzalutamide. JAMA oncology. 2025 Feb;11(2):182–183.

Published In

JAMA oncology

DOI

10.1001/jamaoncol.2024.5661

EISSN

2374-2445

ISSN

2374-2437

Publication Date

February 2025

Volume

11

Issue

2

Start / End Page

182 / 183

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 1117 Public Health and Health Services
  • 1112 Oncology and Carcinogenesis